<DOC>
	<DOCNO>NCT00000433</DOCNO>
	<brief_summary>The Division Rheumatology University California San Francisco conduct research study treatment ankylose spondylitis ( AS ) new therapy currently use people form arthritis . The drug , call Enbrel ( etanercept ) , protein give twice weekly injection underneath skin . It block action tumor necrosis factor-alpha ( TNF-alpha ) , substance may involve AS , rheumatoid arthritis , inflammatory condition . We randomly assign patient receive either drug placebo ( inactive treatment ) 4 month . The result monitor include morning stiffness , spinal mobility , activity daily life , safety drug .</brief_summary>
	<brief_title>Blocking Tumor Necrosis Factor Ankylosing Spondylitis</brief_title>
	<detailed_description>In Phase II clinical trial use tumor necrosis factor receptor p75 fusion protein ( TNFR : Fc , etanercept ) treat patient ankylose spondylitis ( AS ) . TNFR : Fc antagonist tumor necrosis factor ( TNF ) , cytokine researcher show play possible role disease pathogenesis ankylose spondylitis , rheumatoid arthritis , vasculitis , well inflammatory condition . TNFR : Fc consist two molecule extracellular portion p75 receptor , consist 235 amino acid . The two receptor fuse Fc portion human IgG1 , consist 232 amino acid . The gene fragment encode truncated TNFR Fc portion human IgG1 express Chinese hamster ovary cell line . Recent observation animal human study suggest tumor necrosis factor-alpha ( TNF-alpha ) may play role disease activity AS seronegative spondyloarthropathies . This study aim test efficacy TNFR : Fc use conjunction standard medication treatment AS . We give patient either 25mg TNFR : Fc placebo subcutaneously twice week 4 month . Outcome measure include measure function , pain , morning stiffness , patient global assessment , swell joint count , well safety measure .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Diagnosis Ankylosing spondylitis Acceptable stable treatment study : oral glucocorticoid ( less equal 10 mg/d ) and/or NSAIDs recommend dos and/or one follow option : methotrexate ( less equal 20.0 mg/week ) ; sulfasalazine ( less equal 3 grams/d ) ; azathioprine ( less equal 2 mg/kg/d ) ; methotrexate sulfasalazine combination dos list ; 6mercaptopurine ( less equal 1.5 mg/kg/d ) Diagnosis psoriatic arthritis , inflammatory bowel disease , reactive arthritis , Beh√Ωet disease Significant medical problem , diabetes mellitus History active recurrent infection Complete ankylosis entire spine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2003</verification_date>
	<keyword>Spondylitis</keyword>
	<keyword>Etanercept</keyword>
	<keyword>ENBREL</keyword>
	<keyword>Tumor necrosis factor-alpha</keyword>
</DOC>